- Company
- Cosentyx begins competition in the market
- by Aug 30, 2021 05:54am
- As Interleukin-17 (IL-17) sanctions enter the primary biological formulation benefit range for psoriasis arthritis, they will compete in earnest with TNF-α inhibitors. Cosentyx (Secukinumab) of Novartis expanded health insurance benefits from psoriasis arthritis to primary biological sanctions on the 1st. Cosentyx can be used if it meets c
- Company
- Shingles vaccine market overwhelmed by COVID-19… drops 60%
- by An, Kyung-Jin Aug 27, 2021 05:59am
- The domestic market for shingles is shrinking at a fast pace. With vaccinations for COVID-19 ongoing in earnest from earlier this year and the new ‘Delta variant’ intensifying the resurgence of COVID-19 cases, sales of the two shingles vaccines have dropped together. According to the pharmaceutical research institution IQVIA on the 26th, th
- Company
- Korea Pharma has signed a contract to supply Accrufer
- by Aug 27, 2021 05:59am
- Korea Pharma announced on Monday that it has signed an exclusive contract with Shield Theapeutics to supply the anaemic drug Accrufer in Korea. Anemia is very common in patients with inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Poor treatment of anemia increases the morbidity and morbidity of cardiovascular disease. A
- Company
- Who will head Novartis Korea after Joshi Venugopal?
- by Eo, Yun-Ho Aug 26, 2021 05:58am
- The president of Novartis Korea is expected to change soon. According to industry sources, Joshi Venugopal, who had led Novartis Korea since September 2018, has completed his term at the end of last month and made a promotional transfer to become the Global Head of New Products at Novartis headquarters. Novartis Korea’s Chief Finance
- Company
- GSK will supply Fluarix Tetra through Kwang Dong
- by Aug 26, 2021 05:58am
- GSK has signed a contract with Kwang Dong, which has disrupted discussions between SK Bioscience and Fluarix Tetra. GSK announced on the 24th that it has advertised and signed a joint sales contract with the flu vaccine Fluarix Tetra as a new partner. Initially, GSK discussed co-sale of Fluarix Tetra with SK Bioscience, which decided n
- Company
- MSD’s Keytruda becomes the 'symbol' of cancer immunotherapy
- by Eo, Yun-Ho Aug 25, 2021 05:57am
- “Reinforcing the body’s immunity to attack cancer cells” By some, the idea was regarded improbable. Not many were convinced that immunotherapy would rise to the position it is in now. Even without reference to the famous story of how the former US president Jimmy Carter cured melanoma with immunotherapy, cancer immunotherapy has
- Company
- Keytruda monopolizes the domestic pharmaceutical market
- by Chon, Seung-Hyun Aug 24, 2021 06:06am
- MSD's immuno-cancer drug Keytruda has taken the lead in the domestic pharmaceutical market for the sixth consecutive period since the first quarter of last year. New drugs recently released by domestic and foreign pharmaceutical companies such as Perjeta, Prolia, and K-CAB are growing. According to IQVIA, a pharmaceutical research firm on the
- Company
- Tylenol sales jump 140% due to the pandemic
- by Chon, Seung-Hyun Aug 24, 2021 06:05am
- Sales of the OTC antipyretic analgesic ‘Tylenol’ have soared. With the increased demand among people receiving the COVID-19 vaccinations, Tylenol sold &8361;43.6 billion in the first half of this year, which is twice more than that sold in the whole term of last year. There has been criticism that the government’s recommendation to take Tyle
- Company
- Ono Pharma Korea’s Braftovi has been approved in Korea
- by Aug 24, 2021 06:05am
- Ono Pharma Korea announced on the 23rd that it has been approved by the MFDS on the 19th by Braftovi (Encorafenib), a direct bowel cancer treatment. BRAF inhibitor Braftovi can be used as a combination therapy with Erbitux (Cetuximab) in adult patients with direct colon cancer with previous treatment experience and confirmed BRAF V600E mut
- Company
- Will the issue of GLT-2 inhibitors be resolved in 3 years?
- by Eo, Yun-Ho Aug 23, 2021 10:28pm
- Attention is focusing on whether the issue of combined benefits of DPP-4 inhibitors and SGLT-2 inhibitors will finally be solved. According to academia, the HIRA will hold a meeting of experts on September and discuss the combined benefits of oral diabetes treatment DPP-4 inhibitors and SGLT-2 inhibitors. The issue, which has been almost t
